Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Conditions
Interventions
TJ003234
Placebo
Locations
14
United States
University of Arkansas
Little Rock, Arkansas, United States
Olive View-UCLA Medical Center
Sylmar, California, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
The GW Medical Faculty Associates
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
OSF Healthcare Saint Francis Medical Center
Peoria, Illinois, United States
Start Date
April 11, 2020
Primary Completion Date
February 7, 2022
Completion Date
February 7, 2022
Last Updated
May 6, 2023
Lead Sponsor
I-Mab Biopharma US Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions